These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8237826)

  • 1. Controlling cardiac arrhythmias by lengthening repolarization: historical overview.
    Singh BN
    Am J Cardiol; 1993 Nov; 72(16):18F-24F. PubMed ID: 8237826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy.
    Singh BN
    Am J Cardiol; 1993 Nov; 72(16):114F-124F. PubMed ID: 8237824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
    Singh BN
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
    Hohnloser SH
    Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.
    Advani SV; Singh BN
    Drugs; 1995 May; 49(5):664-79. PubMed ID: 7601009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symposium on the management of ventricular dysrhythmias. Antifibrillatory versus antiectopic therapy.
    Anderson JL
    Am J Cardiol; 1984 Jul; 54(2):7A-13A. PubMed ID: 6147079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding clinical role of unique class III antiarrhythmic effects of sotalol.
    Singh BN
    Am J Cardiol; 1990 Jan; 65(2):84A-88A. PubMed ID: 2403738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class III antiarrhythmic agents: the next wave.
    Bauman JL
    Pharmacotherapy; 1997; 17(2 Pt 2):76S-83S; discussion 89S-91S. PubMed ID: 9085343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
    Singh BN; Wadhani N
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):41-53. PubMed ID: 8780328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiologic properties of sotalol and d-sotalol. A current view.
    Touboul P
    Eur Heart J; 1993 Nov; 14 Suppl H():24-9. PubMed ID: 7904935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.
    Hohnloser SH; Singh BN
    J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):920-36. PubMed ID: 8548113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class III antiarrhythmic drugs.
    Singh BN; Ahmed R
    Curr Opin Cardiol; 1994 Jan; 9(1):12-22. PubMed ID: 8199363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia.
    Buchanan LV; Kabell G; Brunden MN; Gibson JK
    J Cardiovasc Pharmacol; 1993 Oct; 22(4):540-9. PubMed ID: 7505355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic effects of antiarrhythmic compounds: intrinsic effects and autonomic modulation.
    Hoffmeister HM; Beyer ME; Seipel L
    Am J Cardiol; 1997 Oct; 80(8A):24G-30G. PubMed ID: 9354409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure.
    Frommeyer G; Milberg P; Witte P; Stypmann J; Koopmann M; Lücke M; Osada N; Breithardt G; Fehr M; Eckardt L
    Eur J Heart Fail; 2011 Oct; 13(10):1060-9. PubMed ID: 21873342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA; Kluger J; White CM
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.